Novo Nordisk A/S (NVO) vs Regeneron Pharmaceuticals (REGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Regeneron Pharmaceuticals (REGN) has outperformed Novo Nordisk A/S (NVO) over the past year, gaining 27.2% versus a loss of 35.2%. Over five years, REGN leads with a +34.1% price change compared with -25.2% for NVO. Novo Nordisk A/S is the larger company by market cap ($167.11 billion vs $75.80 billion), about 2.2 times the size.
On valuation, Novo Nordisk A/S trades at a lower forward P/E (11.4x vs 12.0x for Regeneron Pharmaceuticals). Novo Nordisk A/S offers the higher dividend yield (30.91% vs 0.49%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NVO | REGN |
|---|---|---|
| Share price | $37.86 | $736.21 |
| Market cap | $167.11B | $75.80B |
| 1-day change | -1.06% | -0.80% |
| YTD return | -24.80% | -3.85% |
| 1-year return | -35.17% | +27.24% |
| 5-year return | -25.23% | +34.14% |
| P/E ratio (TTM) | 9.26 | 18.20 |
| Forward P/E | 11.38 | 11.98 |
| EPS (TTM) | $4.09 | $40.44 |
| Dividend yield | 30.91% | 0.49% |
| Annual dividend | $11.70 | $3.64 |
| Revenue (latest FY) | — | $14.34B |
| Revenue growth (YoY) | — | +0.99% |
| Net income (latest FY) | — | $4.50B |
| Operating margin | — | 24.95% |
| Net margin | — | 31.41% |
| 52-week high | $64.16 | $859.34 |
| 52-week low | $35.12 | $541.00 |
| Distance from 52-week high | -41.00% | -14.33% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +21.70% | +16.30% |
| Average volume | 12.54M | 739.67K |
| Shares outstanding | 3.34B | 101.14M |
| Employees | 66,700 | 15,410 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Novo Nordisk A/S is about 2.2 times larger than Regeneron Pharmaceuticals by market value ($167.11B vs $75.80B).
- REGN has outperformed NVO by 62.4 percentage points over the past year.
- Regeneron Pharmaceuticals trades at a higher earnings multiple (18.2x vs 9.3x trailing P/E).
- Novo Nordisk A/S offers a meaningfully higher dividend yield (30.91% vs 0.49%).
About Novo Nordisk A/S
NVO stock →Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 66,700 employees
About Regeneron Pharmaceuticals
REGN stock →Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.
Health Care · Biotechnology: Pharmaceutical Preparations · 15,410 employees
NVO vs REGN FAQ
Which is bigger, Novo Nordisk A/S or Regeneron Pharmaceuticals?
Novo Nordisk A/S (NVO) is larger, with a market capitalization of $167.11B compared with $75.80B for Regeneron Pharmaceuticals (REGN).
Which stock has performed better over the past year, NVO or REGN?
REGN returned +27.24% over the past 12 months, compared with -35.17% for NVO (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, NVO or REGN?
NVO has the lower trailing P/E at 9.3, versus 18.2 for REGN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Novo Nordisk A/S or Regeneron Pharmaceuticals?
Novo Nordisk A/S has the higher yield at 30.91%, compared with 0.49% for Regeneron Pharmaceuticals.
Are Novo Nordisk A/S and Regeneron Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.